Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $225.00

Revolution Medicines (NASDAQ:RVMD) had its price target hoisted by Wedbush from $201.00 to $225.00 in a report released on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other equities analysts have also weighed in on RVMD. Oppenheimer reissued an “outperform” rating and set a $230.00 price objective on shares of Revolution Medicines in a research note on Thursday, August 6th. Piper Sandler lifted their price target on Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Sanford C. Bernstein boosted their price target on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. Royal Bank Of Canada upped their price objective on shares of Revolution Medicines from $182.00 to $203.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Finally, Mizuho raised their price objective on shares of Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $198.89.

Revolution Medicines Trading Down 6.0%

RVMD opened at $207.88 on Thursday. The firm has a market capitalization of $44.56 billion, a price-to-earnings ratio of -23.57 and a beta of 1.39. The company’s 50 day simple moving average is $193.33 and its two-hundred day simple moving average is $148.59. Revolution Medicines has a 1-year low of $37.56 and a 1-year high of $224.31. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the firm posted ($1.31) earnings per share. Analysts expect that Revolution Medicines will post -8.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Revolution Medicines news, COO Margaret A. Horn sold 60,400 shares of Revolution Medicines stock in a transaction on Monday, June 15th. The stock was sold at an average price of $160.17, for a total value of $9,674,268.00. Following the sale, the chief operating officer owned 158,222 shares in the company, valued at $25,342,417.74. The trade was a 27.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark A. Goldsmith sold 80,000 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the transaction, the insider directly owned 267,330 shares in the company, valued at approximately $55,925,436. This trade represents a 23.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 212,497 shares of company stock valued at $38,206,486 in the last ninety days. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Revolution Medicines

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LP lifted its position in Revolution Medicines by 5.9% in the second quarter. Corient Private Wealth LP now owns 10,537 shares of the company’s stock valued at $1,973,000 after buying an additional 583 shares during the last quarter. HighTower Advisors LLC increased its position in shares of Revolution Medicines by 311.2% during the second quarter. HighTower Advisors LLC now owns 10,485 shares of the company’s stock valued at $1,964,000 after acquiring an additional 7,935 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Revolution Medicines by 26,920.9% during the second quarter. California State Teachers Retirement System now owns 44,659,351 shares of the company’s stock valued at $8,363,803,000 after acquiring an additional 44,494,074 shares during the last quarter. Washington Trust Advisors Inc. purchased a new stake in shares of Revolution Medicines in the 2nd quarter valued at approximately $90,000. Finally, Readystate Asset Management LP raised its stake in shares of Revolution Medicines by 18.5% in the 2nd quarter. Readystate Asset Management LP now owns 37,727 shares of the company’s stock valued at $7,066,000 after acquiring an additional 5,880 shares during the period. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.